Biological determinants of responsiveness to growth hormone: Pharmacogenomics and personalized medicine

Endocrine Development

Volumn 18, Issue , 2010, Pages 67-82

  Mullis, Primus E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HOMEODOMAIN PROTEIN; PROTEIN SHORT STATURE HOMEOBOX; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT5B PROTEIN; UNCLASSIFIED DRUG;

DNA POLYMORPHISM; FRAMESHIFT MUTATION; GROWTH REGULATION; HETEROZYGOSITY; HUMAN; MISSENSE MUTATION; NONSENSE MUTATION; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SHORT STATURE;

CHILD; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84925872156     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000316128     Document Type: Review

References (78)

1. Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl 1989;52:1-125.
2. Mullis PE: Genetic control of growth. Eur J Endocrinol 2005;152:11-31.
3. Hindmarsh P, Smith PJ, Brook CG, Matthews DR: The relationship between height velocity and growth hormone secretion in short prepubertal children. Clin Endocrinol (Oxf) 1987;27:581-591.
4. Dammacco F, Boghen MF, Camanni F, Cappa M, Ferrari C, Ghigo E, Giordano G, Loche S, Minuto F, Mucci M, et al: Somatotropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. The Italian Collaborative Group of Neuroendocrinology. J Clin Endocrinol Metab 1993;77:68-72.
5. Rogol AD, Blethen SL, Sy JP, Veldhuis JD: Do growth hormone (GH) serial sampling, insulinlike growth factor-1 (IGF-1) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy? Clin Endocrinol (Oxf) 2003;58:229-237.
6. Hindmarsh P: Endocrine assessment and principles of endocrine testing; in Kelnar C, Savage M, Saenger P, Cowell C (eds): Growth disorders. London, Hodder Arnold, 2007, pp 219-229.
7. Mitchell H, Dattani MT, Nanduri V, Hindmarsh PC, Preece MA, Brook CG: Failure of IGF-1 and IGFBP-3 to diagnose growth hormone insufficiency. Arch Dis Child 1999;80:443-447.
8. Rosenfeld RG: Pharmacogenomics and pharmacoproteomics in the evaluation and management of short stature. Eur J Endocrinol 2007;157(suppl 1):S27-S31.
9. Thomas FJ, McLeod HL, Watters JW: Pharmacogenomics: the influence of genomic variation on drug response. Curr Top Med Chem 2004;4: 1399-1409.
10. Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S, Johanson A: Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. J Clin Endocrinol Metab 1997;82:418-420.
11. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999;84: 1174-1183.
12. Raz B, Janner M, Petkovic V, Lochmatter D, Eble A, Dattani MT, Hindmarsh PC, Fluck CE, Mullis PE: Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 2008;93: 974-980.
13. Rosenfeld RG: The pharmacogenomics of human growth. J Clin Endocrinol Metab 2006;91:795-796.
14. Ranke MB, Lindberg A, Chatelain P, Wilton P, Price DA, Albertsson-Wikland K: The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Pharmacia International Growth Database. Horm Res 2001;55(suppl 2):44-48.
15. Weinshilboum R, Wang L: Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004;3: 739-748.
16. Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentration of growth hormone - a new inborn error of metabolism? Isr J Med Sci 1966;2:152-155.
17. Rosenfeld RG, Hwa V: Toward a molecular basis for idiopathic short stature. J Clin Endocrinol Metab 2004;89:1066-1067.
18. Rosenfeld RG, Kofoed E, Little B, Woods K, Buckway C, Pratt K, Hwa V: Growth hormone insensitivity resulting from post-GH receptor defects. Growth Horm IGF Res 2004;14(suppl A):S3- 5-S38.
19. Bougneres P, Goffin V: The growth hormone receptor in growth. Endocrinol Metab Clin North Am 2007;36:1-16.
20. Maamra M, Milward A, Esfahani HZ, Abbott LP, Metherell LA, Savage MO, Clark AJ, Ross RJ: A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signaling. J Endocrinol 2006;188:251-261.
21. Metherell LA, Akker SA, Munroe PB, Rose SJ, Caulfield M, Savage MO, Chew SL, Clark AJ: Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. Am J Hum Genet 2001;69:641-646.
22. Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, Preece MA, Craescu CT, Blouquit Y, Goossens M, et al: A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J 1994;13:1386-1395.
23. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ: Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005;12:814-821.
24. Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ: New insights into growth hormone action. J Mol Endocrinol 2006;36:1-7.
25. Ross RJ, Esposito N, Shen XY, Von Laue S, Chew SL, Dobson PR, Postel-Vinay MC, Finidori J: A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol 1997; 11:265-273.
26. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, Buchanan CR, Clayton PE, Norman MR: A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 1997;16:13-14.
27. Milward A, Metherell L, Maamra M, Barahona MJ, Wilkinson IR, Camacho-Hubner C, Savage MO, Bidlingmaier CM, Clark AJ, Ross RJ, Webb SM: Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT5 signal transduction. J Clin Endocrinol Metab 2004;89:1259-1266.
28. Tiulpakov A, Rubtsov P, Dedov I, Peterkova V, Bezlepkina O, Chrousos GP, Hochberg Z: A novel C-terminal growth hormone receptor (GHR) mutation results in impaired GHR-STAT5 but normal STAT-3 signaling. J Clin Endocrinol Metab 2005;90:542-547.
29. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V: Defects in growth hormone receptor signaling. Trends Endocrinol Metab 2007;18:134-141.
30. Goddard AD, Dowd P, Chernausek S, Geffner M, Gertner J, Hintz R, Hopwood N, Kaplan S, Plotnick L, Rogol A, Rosenfield R, Saenger P, Mauras N, Hershkopf R, Angulo M, Attie K: Partial growth-hormone insensitivity: the role of growthhormone receptor mutations in idiopathic short stature. J Pediatr 1997;131:S51-55.
31. Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM: Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med 1995;333:1093-1098.
32. Sanchez JE, Perera E, Baumbach L, Cleveland WW: Growth hormone receptor mutations in children with idiopathic short stature. J Clin Endocrinol Metab 1998;83:4079-4083.
33. Woods KA, Dastot F, Preece MA, Clark AJ, Postel- Vinay MC, Chatelain PG, Ranke MB, Rosenfeld RG, Amselem S, Savage MO: Phenotype:genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3529-3535. (Pubitemid 27509332)
34. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH: Growth in growth hormone insensitivity. Trends Endocrinol Metab 1994;5: 296-303.
35. Johnston LB, Pashankar F, Camacho-Hubner C, Savage MO, Clark AJ: Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature. Clin Endocrinol (Oxf) 2000;52:463-469.
36. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST: Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006;145:749-757.
37. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S: Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 2000;275:18664-18669.
38. Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U, Amselem S: Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. J Clin Endocrinol Metab 2003;88:1705-1710.
39. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ: Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on firstyear growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 2006;91:1076-1080.
40. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P: A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004;36:720-724.
41. Carrascosa A, Esteban C, Espadero R, Fernandez- Cancio M, Andaluz P, Clemente M, Audi L, Wollmann H, Fryklund L, Parodi L: The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 g/kg per day) or the spontaneous growth in short non- GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J Clin Endocrinol Metab 2006;91:3281-3286.
42. Binder G, Baur F, Schweizer R, Ranke MB: The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-forgestational- age children. J Clin Endocrinol Metab 2006;91:659-664.
43. Pilotta A, Mella P, Filisetti M, Felappi B, Prandi E, Parrinello G, Notarangelo LD, Buzi F: Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GHdeficient children. J Clin Endocrinol Metab 2006; 91:1178-1180.
44. Audi L, Esteban C, Carrascosa A, Espadero R, Perez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L, Parodi LA: Exon 3-deleted/ full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA. J Clin Endocrinol Metab 2006;91:5038-5043.
45. Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, Amselem S: The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab 2006;91:4171-4174.
46. Audi L, Carrascosa A, Esteban C, Fernandez- Cancio M, Andaluz P, Yeste D, Espadero R, Granada ML, Wollmann H, Fryklund L: The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study. J Clin Endocrinol Metab 2008;93:2709-2715.
47. Van der Klaauw AA, van der Straaten T, Baak- Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JW, Romijn JA: Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2008;93:2828-2834.
48. Carrascosa A, Audi L, Fernandez-Cancio M, Esteban C, Andaluz P, Vilaro E, Clemente M, Yeste D, Albisu MA, Gussinye M: The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. J Clin Endocrinol Metab 2008;93:764-770.
49. Toyoshima MT, Castroneves LA, Costalonga EF, Mendonca BB, Arnhold IJ, Jorge AA: Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature. Clin Endocrinol (Oxf) 2007;67:500-504.
50. Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB: Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: Analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047-2054.
51. Xu S: Theoretical basis of the Beavis effect. Genetics 2003;165:2259-2268.
52. Beavis W: QTL analyses: power, precision and accuracy; in Paterson A (ed): Molecular Dissection of Complex Traits. Boca Raton, CRC Press, 1998, pp 145-161.
53. Carrascosa A, Audi L, Esteban C, Fernandez- Cancio M, Andaluz P, Gussinye M, Clemente M, Yeste D, Albisu MA: Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH therapy in short smallfor- gestational-age children. J Clin Endocrinol Metab 2008;93:147-153.
54. Zhu T, Goh EL, Graichen R, Ling L, Lobie PE: Signal transduction via the growth hormone receptor. Cell Signal 2001;13:599-616.
55. Rojas-Gil AP, Ziros PG, Diaz L, Kletsas D, Basdra EK, Alexandrides TK, Zadik Z, Frank SJ, Papathanassopoulou V, Beratis NG, Papavassiliou AG, Spiliotis BE: Growth hormone/JAK-STAT axis signal-transduction defect. A novel treatable cause of growth failure: FEBS J 2006;273:3454-3466.
56. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD: PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002;70:1555-1563.
57. Carter-Su C, Rui L, Stofega MR: SH2-B and SIRP: JAK2 binding proteins that modulate the actions of growth hormone. Recent Prog Horm Res 2000; 55:293-311.
58. Stofega MR, Herrington J, Billestrup N, Carter-Su C: Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5b. Mol Endocrinol 2000;14:1338-1350.
59. Binder G, Neuer K, Ranke MB, Wittekindt NE: Ptpn11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005;90:5377-5381.
60. Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, Vidaud M, Le Bouc Y: Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 2006;91:300-306.
61. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP: Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-336.
62. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS: Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000;405:1069-1073.
63. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD, Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS, Hilton DJ: SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 2005;115:397-406.
64. Vajo Z, Francomano CA, Wilkin DJ: The molecular and genetic basis of fibroblast growth factor receptor-3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000;21:23-39.
65. Olney RC, Bukulmez H, Bartels CF, Prickett TC, Espiner EA, Potter LR, Warman ML: Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab 2006;91:1229-1232.
66. Tanner JM: The regulation of human growth. Child Dev 1963;34:817-847.
67. Cutler GB Jr: The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 1997;61:141-144.
68. Nilsson O, Baron J: Impact of growth plate senescence on catch-up growth and epiphyseal fusion. Pediatr Nephrol 2005;20:319-322. (Pubitemid 40309936)
69. Nilsson O, Marino R, De Luca F, Phillip M, Baron J: Endocrine regulation of the growth plate. Horm Res 2005;64:157-165.
70. Emons JA, Boersma B, Baron J, Wit JM: Catch-up growth: testing the hypothesis of delayed growth plate senescence in humans. J Pediatr 2005;147: 843-846. (Pubitemid 41774845)
71. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, Zagar AJ, Quigley CA: Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:3406-3416.
72. Quigley CA: Growth hormone treatment of nongrowth hormone-deficient growth disorders. Endocrinol Metab Clin North Am 2007;36:131-186.
73. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54-63.
74. Huber C, Rosilio M, Munnich A, Cormier-Daire V: High incidence of SHOX anomalies in individuals with short stature. J Med Genet 2006; 43:735-739.
75. Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL, Braun L, Rappold G: Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:219-228.
76. Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, Ross JL, Niesler B: Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet 2007;44:306-313.
77. Marchini A, Rappold G, Schneider KU: SHOX at a glance: From gene to protein. Arch Physiol Biochem 2007;113:116-123.
78. Ogata T, Matsuo N, Nishimura G: SHOX haploinsufficiency and overdosage: impact of gonadal function status. J Med Genet 2001;38:1-6.